NCT02047461: A reported trial by Origin Biosciences
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02047461 |
|---|---|
| Title | A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ORGN001 (Formerly ALXN1101) in Pediatric Patients With Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated With Recombinant Escherichia Coli-derived Cyclic Pyranopterin Monophosphate (rcPMP) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 30, 2014 |
| Completion date | Aug. 31, 2022 |
| Required reporting date | Aug. 31, 2023, midnight |
| Actual reporting date | Aug. 10, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |